ClinicalTrials.gg
CompletedNCT05967858Updated Aug 14, 2023

Incidence of Refeeding Syndrome in Consecutively Admitted Patients

An observational study in Refeeding Syndrome, Starvation and Phosphate Deficiency, sponsored by Jens Rikardt Andersen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Jens Rikardt Andersen · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
51
Ages
18 Years and older
Sex
All
01

Study summary

The incidence and main risk-factors analyzed in consecutive in-patients in the departments og gastroenterology and ear-nose and throat diseases (cancer in radiation therapy)

Read the detailed description

Patients with either parenteral- or tube feeding enter the study to assure sufficient nutrition.

During hospitalization patients were monitored with daily blood samples and clinical evaluation of symptoms in addition to the coverage of energy and protein in percent of estimated needs.

Refeeding phenomenon was defined as a decrease in plasma phosphate after the initiation of nutrition.

Refeeding syndrome as refeeding phenomenon and one or more relevant symptoms in addition (hypotension, cardiac arrhythmia, edema, confusion)

02

Conditions studied

  • Refeeding Syndrome
  • Starvation
  • Phosphate Deficiency

Browse trials for

03

In context

Refeeding Syndrome

24 studies on the registry are indexed under Refeeding Syndrome; 7 are open to participants now.

This study's enrollment of 51 is below the median of 57 across 16 observational studies indexed under Refeeding Syndrome.

Browse Refeeding Syndrome studies →

Lead sponsor

Jens Rikardt Andersen is the lead sponsor of 24 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

No other than willingness to participate and consecutively admitted, as well as planned sufficient nutrition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • planned tube- or parenteral nutrition (complete or supplementary)
  • > 18 years
  • written consent

Exclusion criteria

Exclusion Criteria:

  • Renal insufficiency (p-creatinine >200 micromol/l)
  • Lack of ability to communicate (registration of nutritional intake etc)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
51 participants (actual)
Patient registry
No

Groups and cohorts

  • gastroenterological

    Consecutive admissions - n= 43 - 34 operated (79%) - 10 patients acutely admitted Diseases in Esophagus (8), gastric cavity (8), pancreas (7), colon/rectum (8), bile (4), small intestine (3), IBD (5) No interventions in the treatments, just observation

    Other: observation

  • head and neck cancer

    Consecutive admissions - n=8 - 7 radiation therapy - 1 operated Locations: 2 Larynx, 1 oro-pharynx, 4 tonsillar, 1 tung No interventions in the treatments, just observation

    Other: observation

Interventions

  • Otherobservation

    no intervention

06

What researchers measure

Primary outcomes

  1. Refeeding syndrome

    No. patients with decrease in plasma phosphate + clinical symptoms

    Time frame: 1 week after start of nutrition

Secondary outcomes

  1. Refeeding phenomenon

    No. patients with decrease in plasma phosphate after start of nutrition

    Time frame: 1 week after start of nutrition

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in May 2014, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartActual
Dec 1, 2013
Primary completionActual
May 31, 2014
CompletionActual
Jul 1, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05967858
Lead sponsor
Jens Rikardt Andersen
Collaborators
St. Olavs Hospital
Responsible party
Jens Rikardt Andersen (Assoc Prof, University of Copenhagen) — Sponsor-investigator
First posted
Aug 1, 2023
Start date
Dec 1, 2013
Primary completion
May 31, 2014
Completion
Jul 1, 2023
Last update
Aug 14, 2023

Study contacts

jens R Andersen, MD, MPA
study chair · University of Copenhagen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion